Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Cold Agglutinin Disease
NCT01303952Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Jan 2011
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in cold agglutinin disease (CAD), sponsored by Universitätsmedizin Essen. Started Jan 2011; status: completed.
02
Drugs
eculizumab
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT01303952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303952.